unknown
Stage
1
Investors
About
Context Therapeutics develops next-generation bispecific T cell engager antibody therapies targeting solid tumors to harness the immune system for cancer treatment.
Explore Context Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.